Indication
Dimethyl fumarate Teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS).
Loading your page…
Loading your page…
Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis
Marketing Authorisation Holder: Teva GmbH
EMA Authorisation: 12/12/2022
INN: dimethyl fumarate
AI Drug & Interaction Analysis
Free account required
Ask Osler about Dimethyl fumarate Teva: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.